Table 2.

Comparative analysis of the association between the use of SGLT2 inhibitors and DPP-4 inhibitors in terms of the risk of urogenital bacterial infections

Outcome	Before PS matching		After PS matching
	SGLT2 inhibitors (n = 34,897)	DPP-4 inhibitors (n = 135,311)	SGLT2 inhibitors (n = 31,665)	DPP-4 inhibitors (n = 31,665)
Urinary tract infections
No of events	1293	5377	1130	1038
Incidence rate†	24.35	27.84	23.73	27.44
Hazard ratio (95% CI)	0.88 (0.83–0.93)		0.90 (0.83–0.98)
Genital bacterial infections
No of events	374	889	321	216
Incidence rate†	6.88	4.46	6.59	5.56
Hazard ratio (95% CI)	1.55 (1.37–1.74)		1.23 (1.03–1.46)
Perineal soft tissue infections
No of events	31	101	30	23
Incidence ratea	0.57	0.50	0.61	0.59
Hazard ratio (95% CI)	1.15 (0.77–1.72)		1.05 (0.61–1.81)

PS propensity score, SGLT2 sodium glucose cotransporter 2, DPP-4 dipeptidyl peptidase-4, CI confidence interval

^aPer 1000 person-years of follow-up